GSK sees rise in sales of vaccines, healthcare products

April 27, 2016

Pharmaceutical company GlaxoSmithKline says higher sales of vaccines and consumer healthcare products pushed up its earnings from core business by 19 percent in the first quarter.

Core operating profit, which excludes taxes, one-time items and restructuring costs, rose to 1.56 billion pounds ($2.28 billion) from 1.31 billion pounds in the same quarter a year earlier.

Sales of vaccines rose 23 percent to 882 million pounds and of consumer healthcare increased 26 percent to 1.76 billion pounds. Pharmaceutical sales fell 1 percent to 3.59 billion pounds, hurt by competition for the Advair asthma treatment.

Like many big companies, GSK is struggling to develop new blockbuster drugs as older treatments lose patent protection.

Chief Executive Andrew Witty says the results demonstrate the momentum across the group "driven by growth in sales of our new products, effective cost control and execution of our restructuring and integration plans."

Net income, which includes all income and expenses, fell 97 percent to 282 million pounds after the company reported a 9.3 billion pound gain on the sale of its oncology unit and other assets in the first quarter of 2015.

Explore further: Novartis profits dip as generic rival challenges cancer drug

Related Stories

Novartis profits dip as generic rival challenges cancer drug

April 21, 2016
Swiss pharmaceuticals maker Novartis says net income from continued operations fell 13 percent in the first quarter as generic competition cut into sales of Gleevec, one of the first very effective cancer medicines.

Divestment gains boost net earnings at drug company Novartis

April 23, 2015
Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies.

GlaxoSmithKline opts to hold on to HIV business

May 6, 2015
British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.

Novartis income drops 42 pct in Q3 after sale a year earlier

October 27, 2015
Swiss pharmaceutical giant Novartis says net income fell 42 percent in the third quarter, largely due to the sale of its hepatitis drug unit a year earlier and provisions for legal settlements and fees.

Recommended for you

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.